Table 2

Results from logistic regression models

	Effectiveness			Tolerability
	OR	95% CI	P value	OR	95% CI	P value
Baseline parameter
Satisfaction at baseline	2.98	2.58 to 3.44	<0.0001	2.40	2.03 to 2.83	<0.0001
Seropositivity	1.36	1.17 to 1.57	<0.0001	1.22	1.04 to 1.43	0.0129
≥1 bDMARD prior to enrolment	0.78	0.66 to 0.92	0.0042	0.97	0.79 to 1.21	0.8134
Depression	0.64	0.51 to 0.80	<0.0001	0.54	0.43 to 0.68	<0.0001
Fibromyalgia	0.70	0.51 to 0.96	0.0257	0.79	0.56 to 1.10	0.1656
Obesity (BMI ≥30 kg/m², ref. <30 kg/m²)	0.86	0.74 to 0.99	0.0377	0.93	0.78 to 1.11	0.4485
Heart failure	1.23	0.77 to 1.98	0.3884	0.92	0.58 to 1.45	0.7151
Diabetes	0.93	0.74 to 1.17	0.5468	0.87	0.70 to 1.08	0.2023
Chronic kidney disease	0.97	0.71 to 1.32	0.8467	1.05	0.71 to 1.55	0.8145
Malignant neoplasm	1.02	0.71 to1.45	0.9249	0.93	0.64 to 1.35	0.7041
Degenerative spine disease	0.93	0.76 to 1.12	0.4309	0.87	0.71 to 1.06	0.1611
Osteoarthritis	0.90	0.75 to 1.07	0.2416	0.94	0.78 to 1.13	0.4801
Osteoporosis	0.93	0.77 to 1.12	0.4491	0.98	0.79 to 1.22	0.8527
Age at onset (10 years)	1.04	0.98 to 1.10	0.1792	1.00	0.94 to 1.06	0.9362
Female sex	1.08	0.92 to 1.28	0.3344	1.12	0.93 to 1.36	0.2372
Former smoking	0.91	0.76 to 1.08	0.2702	0.96	0.79 to 1.16	0.6685
Current smoking	0.96	0.80 to 1.15	0.6586	0.99	0.83 to 1.19	0.9421
No information on smoking	1.12	0.77 to 1.62	0.5517	0.92	0.65 to 1.30	0.6398
Parameter after 12 months
DAS28-ESR reduction by 1 point	1.38	1.31 to 1.46	<0.0001	1.31	1.24 to 1.39	<0.0001
Pain reduction by 1 point	1.26	1.22 to 1.31	<0.0001	1.13	1.09 to 1.17	<0.0001
Increase in physical capacity by 10 points	1.22	1.17 to 1.29	<0.0001	1.11	1.05 to 1.17	0.0004
Fatigue reduction by 1 point	1.02	0.98 to 1.05	0.3601	1.04	1.00 to 1.08	0.0303
Sleeping disorder reduction by 1 point	1.02	0.99 to 1.05	0.3188	1.03	1.00 to 1.06	0.0632
Glucocorticoids 5 to <10 mg/day, ref. <5 mg	0.81	0.71 to 0.92	0.0019	0.86	0.74 to 1.00	0.0439
Glucocorticoids 10 to <15 mg/day, ref. <5 mg	0.46	0.34 to 0.62	<0.0001	0.50	0.37 to 0.67	<0.0001
Glucocorticoids ≥15 mg/day, ref. <5 mg	0.24	0.16 to 0.35	<0.0001	0.46	0.30 to 0.70	0.0004
≥1 change of therapy after enrolment	0.63	0.55 to 0.73	<0.0001	0.65	0.55 to 0.76	<0.0001
b/tsDMARD therapy	1.14	0.98 to 1.34	0.0982	1.18	1.00 to 1.39	0.0504

Effects statistically significant at level α=0.05 are marked in bold.
bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; DAS28-ESR, Disease Activity Score in 28 joints-erythrocyte sedimentation rate; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.